Clinical Commander

Back to dossier
cardio.cardiogenic-shock.ccb-overdose.v1PRODUCTION
cardio.cardiogenic-shock.ccb-overdose.v1

Cardiogenic shock — Calcium channel blocker overdose (HIE-first toxicologic CS)

cardiologyacuteadult
Hard-required inputs
0 / 15
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Recognize CCB OD as toxicologic CS — Ca-channel blockade defeats standard pressors; HIE + calcium + lipid emulsion + methylene blue (DHP) are pillars; standard NE / vasopressin alone often inadequate

Inputs
2
Actions
0
Advance rule
Set
Advance when

CCB OD with shock physiology confirmed

Patient inputs (15)

Pediatric single-tablet CCB ingestion (esp amlodipine, verapamil-SR) catastrophic; geriatric polypharmacy compounds toxicity

Hypothermia common in severe CCB OD; warm to ≥36°C before pronouncement of refractoriness

eGFR for supportive drug dosing (most CCBs NOT dialyzable due to high Vd + protein binding); CRRT for AKI from sustained shock

Identify specific CCB (amlodipine = long t½ + vasoplegia; verapamil = highest mortality + bradycardia; diltiazem intermediate; sustained-release formulations have delayed peak); dose in mg/kg; coingestants

Concurrent BB / TCA / opioid / EtOH; BB co-ingestion is the highest-mortality phenotype — early VA-ECMO planning

CCB OD impairs pancreatic insulin release (Ca-dependent) → HYPERGLYCEMIA at presentation (distinguishes from BB OD which causes hypoglycemia); during HIE, target euglycemia 100–250 with D10W

Insulin shifts K intracellularly during HIE — replace aggressively (K target ≥4.0); hourly during HIE infusion

Differentiate primary toxic CS from ischemia-precipitated shock; modest elevations common from low-flow

Bradycardia + AV block (non-DHP); usually preserved sinus + normal PR (DHP); QRS narrow (no Na-channel effect, distinct from propranolol BB OD); QT typically not prolonged

Reduced contractility (non-DHP cardiogenic phenotype) vs hyperdynamic + low SVR (amlodipine vasoplegic phenotype) — distinguishes management focus; serial echo to track HIE inotropic recovery

SCAI 2022 baseline + vasopressor titration; persistent SBP <90 despite HIE + pressors → MCS escalation

Bradycardia (HR <60) + AV block hallmark of non-DHP OD; reflex tachycardia possible in early DHP OD before vasoplegia decompensates

SCAI 2022 staging + perfusion marker; CardShock prognostication (Harjola PMID 26333869)

HIE dosing weight-based (insulin 1 U/kg bolus → 0.5–2 U/kg/h); calcium gluconate 3 g per dose; lipid emulsion 1.5 mL/kg bolus

Track ionized Ca during high-dose calcium therapy; target ionized Ca >2.0 (avoid hypercalcemia toxicity > 3.0)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningamlodipine_vasoplegia_refractory_to_ne
    Amlodipine OD with vasoplegic shock refractory to norepinephrine — DHP distributive phenotype with hyperdynamic LV on echo; add vasopressin + HIE + methylene blue; early VA-ECMO planning given amlodipine long t½ (30–50 h)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningdiltiazem_av_block_requiring_pacing
    Diltiazem (or verapamil) OD with 2nd or 3rd-degree AV block + symptomatic bradycardia requiring transvenous pacing — non-DHP cardiogenic phenotype; calcium + HIE + pacing combination
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninghie_failure_in_ccb_od_needs_va_ecmo
    Refractory shock with lactate not clearing despite escalating HIE + calcium + pressors in CCB OD — emergent VA-ECMO bridge while drug clears (24–72 h; longer for amlodipine)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsuicide_risk_with_repeated_ccb_od_or_bb_co_ingestion
    Intentional CCB OD with repeated overdose history OR concurrent BB co-ingestion — highest-mortality phenotype; intensive psych safety planning post medical clearance + prophylactic VA-ECMO team activation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresustained_release_ccb_with_delayed_decompensation
    Sustained-release CCB ingestion (verapamil-SR, diltiazem CD, amlodipine — long t½) with initial stable presentation but delayed decompensation 4–8 h post ingestion — admit and monitor at least 24 h; whole-bowel irrigation + early HIE if any deterioration
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

CCB overdose with CS — HIE-first toxicologic pillars (insulin-euglycemia + high-dose calcium + lipid emulsion + methylene blue for vasoplegia); pressors as adjuncts; VA-ECMO if refractory
axis: ccb_overdose_phenotype
Selected axis "CCB overdose with CS — HIE-first toxicologic pillars (insulin-euglycemia + high-dose calcium + lipid emulsion + methylene blue for vasoplegia); pressors as adjuncts; VA-ECMO if refractory" by default fallback (first axis)
  • insulin regular
    first line
    insulin_short_acting_for_hie
    1 U/kg IV bolus → 0.5–2 U/kg/h continuous infusion (HIE; up to 10 U/kg/h reported) • IV • continuous; titrate up if persistent shock
    triggers: ccb_overdose_with_shock, concurrent_ccb_bb_overdose
    St-Onge meta-analysis 2017 PMID 27767299 + Engebretsen PMID 21626672 — HIE > standard pressors in CCB OD; FIRST-LINE inotropic strategy in toxicologic CS; restores myocyte glucose oxidation + improves vascular tone
    rxcui 253182
  • calcium gluconate
    first line
    electrolyte_calcium_salt
    3 g IV q5 min × max ~12 g, then titrate to ionized Ca >2.0 • IV • q5 min initial then q4–6 h titrate
    triggers: ccb_overdose_with_shock, concurrent_bb_co_ingestion, av_block_in_non_dhp_ccb_od
    CCB-SPECIFIC core therapy — direct antagonism of L-type Ca channel block; trial 3–4 doses; if no response do not exceed safety limit but pivot to HIE + MCS; calcium chloride 10% 1 g central line is alternative (3× more elemental Ca per gram)
    rxcui 1908
  • intralipid 20%
    rescue
    lipid_emulsion_for_lipophilic_od
    1.5 mL/kg IV bolus over 1 min → 0.25 mL/kg/min infusion × 30–60 min (max ~10 mL/kg total) • IV • bolus may repeat × 2 q5 min then continuous
    triggers: severe_amlodipine_overdose, severe_verapamil_overdose, lipophilic_ccb_od_with_shock_or_arrest
    Levine 2014 PMID 25498415 — lipid sink for lipophilic agents (amlodipine log P ~3.0; verapamil also lipophilic; diltiazem intermediate; nifedipine less); rescue in shock or arrest
    rxcui 9949
  • glucagon
    second line
    glucagon_receptor_agonist
    5–10 mg IV bolus → 5–10 mg/h infusion (trial only if response) • IV • continuous if responsive
    triggers: ccb_overdose_with_bradycardia_trial_only
    AACT 2017 PMID 29022414 — LESS effective in CCB than BB OD (no β-blockade defect; cAMP pathway not the primary issue); trial dose; pre-treat with anti-emetic; persist only if clear response
    rxcui 4832
  • norepinephrine
    first line
    vasopressor_alpha_beta
    0.05–0.5 µg/kg/min IV titrate MAP ≥65 • IV • continuous
    triggers: cs_overlay_on_ccb_od, amlodipine_vasoplegia_initial_pressor
    SOAP-II PMID 20200382 — first-line vasopressor in CS; in DHP (amlodipine) vasoplegia, often inadequate alone — combine with vasopressin + methylene blue + HIE
    rxcui 7512
  • vasopressin
    add on
    vasoconstrictor_v1
    0.04 U/min IV continuous • IV • continuous
    triggers: amlodipine_vasoplegia_refractory_to_ne, distributive_phenotype_ccb_od
    V1 pathway intact in vasoplegic shock; spares α-receptor; useful in DHP-induced vasoplegia analogous to septic shock add-on (VASST PMID 18305265)
    rxcui 11149
  • methylene blue
    rescue
    no_cgmp_pathway_inhibitor
    1–2 mg/kg IV bolus over 5 min; may repeat × 1 if partial response • IV • bolus; rarely infusion
    triggers: refractory_amlodipine_vasoplegia_despite_ne_vasopressin_hie
    Inhibits NO-cGMP vasodilation pathway; case-series + small-RCT evidence in distributive vasoplegic shock; reasonable rescue in refractory amlodipine OD; AVOID with serotonergic drugs (serotonin syndrome risk)
    rxcui 6878
  • isoproterenol
    rescue
    beta1_agonist
    2–10 µg/min IV titrate to HR 60–80 • IV • continuous
    triggers: symptomatic_bradycardia_with_pacing_capture_failure_in_ccb_od
    β-1 chronotropic bridge during pacing capture-failure; less commonly needed in CCB OD vs BB OD because β-pathway intact and pacing capture often acceptable
    rxcui 6054
  • atropine
    second line
    antimuscarinic
    0.5–1 mg IV q3–5 min × max 3 mg • IV • q3–5 min
    triggers: symptomatic_bradycardia_in_ccb_od
    AHA 2020 ACLS bradycardia algorithm; usually inadequate in severe CCB OD; transient bridge to calcium / HIE / pacing
    rxcui 1223
  • potassium chloride
    add on
    electrolyte
    20–40 mEq IV/PO; target K ≥4.0 • IV/PO • PRN during HIE — hourly replacement common
    triggers: hypokalemia_during_hie_infusion
    Insulin shifts K intracellularly during HIE — replace aggressively to ≥4.0 to prevent arrhythmia
    rxcui 8591
  • magnesium sulfate
    add on
    electrolyte
    2 g IV bolus then PRN • IV • PRN
    triggers: hypomagnesemia_during_hie, arrhythmia_prophylaxis
    Replace to ≥2.0; arrhythmia prophylaxis during HIE
    rxcui 6585
  • activated charcoal
    add on
    gi_decontamination
    1 g/kg PO/NG if airway protected, ingestion <1 h (<2 h for sustained-release) • PO/NG • one-time
    triggers: recent_ccb_ingestion_within_1_to_2_hours_with_protected_airway
    GI decontamination per AACT/EAPCCT — limited evidence; AVOID if ileus / obtundation without intubation
    rxcui 272
  • whole bowel irrigation with polyethylene glycol
    add on
    gi_decontamination
    PEG-electrolyte solution 1.5–2 L/h via NG until rectal effluent clear • NG • continuous until clear
    triggers: sustained_release_ccb_ingestion_verapamil_sr_diltiazem_cd
    AACT/EAPCCT — recommended for sustained-release CCB ingestion; AVOID if ileus / bowel obstruction / unprotected airway

outpatient playbook — drug actions (2)

  1. 1. continue psych regimen per psychiatry
    per psychiatry • PO • per regimen
    trigger: Underlying psych diagnosis
    Long-term mood stabilization + suicide prevention
  2. 2. lifelong avoidance of CCB unless cardiology shared decision + means restriction
    patient + family education + medic-alert • n/a • lifelong
    trigger: Intentional CCB OD history
    Lethal-means counseling; consider non-CCB alternative for cardiac indications

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Intentional CCB ingestion + bradycardia + AV block + hypotension — non-DHP (diltiazem / verapamil) cardiogenic phenotype; HIE pathway; Amlodipine OD with vasoplegic shock refractory to norepinephrine — DHP distributive phenotype; HIE + methylene blue + vasopressin pathway; ECG bradycardia + 1st/2nd/3rd-degree AV block in known or suspected CCB OD — non-DHP toxicity; calcium + HIE + pacing planning.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — Calcium channel blocker overdose (HIE-first toxicologic CS)** (cardio.cardiogenic-shock.ccb-overdose.v1).
Scope: Recognize CCB OD as toxicologic CS — Ca-channel blockade defeats standard pressors; HIE + calcium + lipid emulsion + methylene blue (DHP) are pillars; standard NE / vasopressin alone often inadequate

No severity triggers fired against current inputs.

Plan

Regimen axis: **CCB overdose with CS — HIE-first toxicologic pillars (insulin-euglycemia + high-dose calcium + lipid emulsion + methylene blue for vasoplegia); pressors as adjuncts; VA-ECMO if refractory**.
1. insulin regular 1 U/kg IV bolus → 0.5–2 U/kg/h continuous infusion (HIE; up to 10 U/kg/h reported) IV continuous; titrate up if persistent shock (insulin_short_acting_for_hie, first line) — St-Onge meta-analysis 2017 PMID 27767299 + Engebretsen PMID 21626672 — HIE > standard pressors in CCB OD; FIRST-LINE inotropic strategy in toxicologic CS; restores myocyte glucose oxidation + improves vascular tone
2. calcium gluconate 3 g IV q5 min × max ~12 g, then titrate to ionized Ca >2.0 IV q5 min initial then q4–6 h titrate (electrolyte_calcium_salt, first line) — CCB-SPECIFIC core therapy — direct antagonism of L-type Ca channel block; trial 3–4 doses; if no response do not exceed safety limit but pivot to HIE + MCS; calcium chloride 10% 1 g central line is alternative (3× more elemental Ca per gram)
3. intralipid 20% 1.5 mL/kg IV bolus over 1 min → 0.25 mL/kg/min infusion × 30–60 min (max ~10 mL/kg total) IV bolus may repeat × 2 q5 min then continuous (lipid_emulsion_for_lipophilic_od, rescue) — Levine 2014 PMID 25498415 — lipid sink for lipophilic agents (amlodipine log P ~3.0; verapamil also lipophilic; diltiazem intermediate; nifedipine less); rescue in shock or arrest
4. glucagon 5–10 mg IV bolus → 5–10 mg/h infusion (trial only if response) IV continuous if responsive (glucagon_receptor_agonist, second line) — AACT 2017 PMID 29022414 — LESS effective in CCB than BB OD (no β-blockade defect; cAMP pathway not the primary issue); trial dose; pre-treat with anti-emetic; persist only if clear response
5. norepinephrine 0.05–0.5 µg/kg/min IV titrate MAP ≥65 IV continuous (vasopressor_alpha_beta, first line) — SOAP-II PMID 20200382 — first-line vasopressor in CS; in DHP (amlodipine) vasoplegia, often inadequate alone — combine with vasopressin + methylene blue + HIE
6. vasopressin 0.04 U/min IV continuous IV continuous (vasoconstrictor_v1, add on) — V1 pathway intact in vasoplegic shock; spares α-receptor; useful in DHP-induced vasoplegia analogous to septic shock add-on (VASST PMID 18305265)
7. methylene blue 1–2 mg/kg IV bolus over 5 min; may repeat × 1 if partial response IV bolus; rarely infusion (no_cgmp_pathway_inhibitor, rescue) — Inhibits NO-cGMP vasodilation pathway; case-series + small-RCT evidence in distributive vasoplegic shock; reasonable rescue in refractory amlodipine OD; AVOID with serotonergic drugs (serotonin syndrome risk)
8. isoproterenol 2–10 µg/min IV titrate to HR 60–80 IV continuous (beta1_agonist, rescue) — β-1 chronotropic bridge during pacing capture-failure; less commonly needed in CCB OD vs BB OD because β-pathway intact and pacing capture often acceptable
9. atropine 0.5–1 mg IV q3–5 min × max 3 mg IV q3–5 min (antimuscarinic, second line) — AHA 2020 ACLS bradycardia algorithm; usually inadequate in severe CCB OD; transient bridge to calcium / HIE / pacing
10. potassium chloride 20–40 mEq IV/PO; target K ≥4.0 IV/PO PRN during HIE — hourly replacement common (electrolyte, add on) — Insulin shifts K intracellularly during HIE — replace aggressively to ≥4.0 to prevent arrhythmia
11. magnesium sulfate 2 g IV bolus then PRN IV PRN (electrolyte, add on) — Replace to ≥2.0; arrhythmia prophylaxis during HIE
12. activated charcoal 1 g/kg PO/NG if airway protected, ingestion <1 h (<2 h for sustained-release) PO/NG one-time (gi_decontamination, add on) — GI decontamination per AACT/EAPCCT — limited evidence; AVOID if ileus / obtundation without intubation
13. whole bowel irrigation with polyethylene glycol PEG-electrolyte solution 1.5–2 L/h via NG until rectal effluent clear NG continuous until clear (gi_decontamination, add on) — AACT/EAPCCT — recommended for sustained-release CCB ingestion; AVOID if ileus / bowel obstruction / unprotected airway

Setting playbook (outpatient) — Long-term psychiatric + cardiology follow-up; safety plan maintenance; medication reconciliation (avoid CCB re-exposure if intentional OD); annual ECG + echo if conduction or contractile recovery incomplete; family / community lethal-means counseling
14. continue psych regimen per psychiatry per psychiatry PO per regimen — Underlying psych diagnosis (Long-term mood stabilization + suicide prevention)
15. lifelong avoidance of CCB unless cardiology shared decision + means restriction patient + family education + medic-alert n/a lifelong — Intentional CCB OD history (Lethal-means counseling; consider non-CCB alternative for cardiac indications)

Non-pharmacologic actions:
- Quarterly psych follow-up; annual / biannual cardiology
- Continued lethal-means counseling + medication storage education
- Crisis hotline (988) + safety plan reinforcement at every visit
- Family education on warning signs

AVOID / contraindication checks:
- Hie_requires_glucose_monitoring_q1h_and_aggressive_K_replacement (insulin shifts K intracellularly; D10W titration to maintain euglycemia 100–250)
- Calcium_titrate_to_ionized_above_2.0_avoid_above_3.0 (hypercalcemia toxicity > 3.0; trial 3–4 doses then pivot to HIE + MCS if no response)
- Glucagon_LESS_effective_in_ccb_than_bb (no β blockade defect; trial dose only; persist only if clear response)
- Lipid_emulsion_for_lipophilic_ccbs (amlodipine, verapamil); limited value for hydrophilic CCBs (nifedipine somewhat less lipophilic)
- Hemodialysis_GENERALLY_NOT_effective_in_ccb_od (high Vd + protein binding); CRRT for AKI from sustained shock only
- Phenylephrine_pure_alpha_LESS_effective_in_non_dhp_ccb_od (does not address inotropic / chronotropic failure)
- Methylene_blue_AVOID_with_serotonergic_drugs (serotonin syndrome risk; SSRIs, SNRIs, MAOIs, linezolid)
- Concurrent_bb_co_ingestion_HIGHEST_mortality_phenotype (early MCS / VA ECMO planning)
- Transvenous_pacing_capture_acceptable_in_ccb_od (vs poor in BB OD); useful bridge while HIE + calcium take effect

Monitoring

Regimen monitoring:
- continuous telemetry with pr interval q4-6h
- arterial line continuous BP
- central line for pressors + calcium chloride + methylene blue
- glucose q1h during hie target 100-250
- potassium q1h during hie replace to above 4.0
- ionized calcium q4-6h during calcium therapy target above 2.0 avoid above 3.0
- magnesium q4-6h replace to above 2.0
- lactate q2-4h until normalised
- UOP hourly
- serial echo q12-24h to distinguish cardiogenic vs distributive phenotype + track recovery
- temperature q1h maintain above 36c (hypothermia common in severe OD)

Setting (outpatient) monitoring:
- Psych quarterly
- Cardiology q3–6 mo year 1; annual thereafter
- Annual ECG + echo if residual abnormality

Follow-up plan: Psychiatric inpatient admission post-medical clearance for intentional OD (mandatory safety planning); Toxicology + Cardiology follow-up at 1–4 wks; outpatient SSRI / mood stabilizer review with psychiatry; medic-alert documentation for severe CCB-sensitivity if therapeutic re-introduction needed; family education on lethal-means counseling (esp removal of long-acting CCBs from home)
- Close-out criterion: Psych admission + safety plan + outpatient cardiology + toxicology follow-up scheduled

Monitoring phase: Continuous telemetry; A-line; central line; serial ECG q4–6 h (track conduction); glucose q1h during HIE (D10W titration; target 100–250); K hourly (insulin shifts intracellularly — replace aggressively to ≥4.0); ionized Ca q4–6 h (target >2.0; avoid >3.0 toxicity); Mg q4–6 h; lactate q2–4 h until clearing; UOP hourly; serial echo q12–24 h to track inotropic recovery + distinguish persistent cardiogenic vs distributive phenotype

Disposition

Current setting: outpatient — Long-term psychiatric + cardiology follow-up; safety plan maintenance; medication reconciliation (avoid CCB re-exposure if intentional OD); annual ECG + echo if conduction or contractile recovery incomplete; family / community lethal-means counseling

Disposition criteria:
- Stable on long-term outpatient regimen with engaged psych + cardiology follow-up; lifelong follow-up

Escalation triggers (move to higher acuity):
- Recurrent suicidal ideation → ED + involuntary hold
- Inadvertent CCB exposure → ED
- Progressive conduction / contractile disease → cardiology + EP

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Amlodipine OD with vasoplegic shock refractory to norepinephrine — DHP distributive phenotype with hyperdynamic LV on echo; add vasopressin + HIE + methylene blue; early VA-ECMO planning given amlodipine long t½ (30–50 h)
- [LIFE_THREATENING] Diltiazem (or verapamil) OD with 2nd or 3rd-degree AV block + symptomatic bradycardia requiring transvenous pacing — non-DHP cardiogenic phenotype; calcium + HIE + pacing combination
- [LIFE_THREATENING] Refractory shock with lactate not clearing despite escalating HIE + calcium + pressors in CCB OD — emergent VA-ECMO bridge while drug clears (24–72 h; longer for amlodipine)

Citations

- AACT 2017 BB+CCB Toxicity Expert Consensus (PMID 29022414); St-Onge 2017 meta-analysis CCB OD (PMID 27767299); Engebretsen 2011 HIE in BB/CCB OD (PMID 21626672); SCAI 2022 CS staging (Naidu PMID 35718438); ACMT HIE position statement; AHA 2020 ACLS [PMID:29022414](https://pubmed.ncbi.nlm.nih.gov/29022414/)
- Cited evidence (PMID 27767299) [PMID:27767299](https://pubmed.ncbi.nlm.nih.gov/27767299/)
- Cited evidence (PMID 21626672) [PMID:21626672](https://pubmed.ncbi.nlm.nih.gov/21626672/)
- Cited evidence (PMID 25498415) [PMID:25498415](https://pubmed.ncbi.nlm.nih.gov/25498415/)
- Cited evidence (PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)

Last reconciled with current guidelines: 2026-05-15.
References
  • AACT 2017 BB+CCB Toxicity Expert Consensus (PMID 29022414); St-Onge 2017 meta-analysis CCB OD (PMID 27767299); Engebretsen 2011 HIE in BB/CCB OD (PMID 21626672); SCAI 2022 CS staging (Naidu PMID 35718438); ACMT HIE position statement; AHA 2020 ACLS — PMID:29022414
  • Cited evidence (PMID 27767299) — PMID:27767299
  • Cited evidence (PMID 21626672) — PMID:21626672
  • Cited evidence (PMID 25498415) — PMID:25498415
  • Cited evidence (PMID 35718438) — PMID:35718438